AstraZeneca Moves Into Self-Amplifying RNA With VaxEquity Deal

Sees Potential Beyond Vaccines

VaxEquity’s founder dropped out of the race to develop a COVID-19 vaccine last year – but it and new partner AstraZeneca see potential not just in vaccines, but therapeutics too.

AstraZeneca
The partners hope VaxEquity's self-ampliftying RNA technology can serve as the basis of therapies as well as vaccines.

AstraZeneca is moving into the field of self-amplifying RNA via a deal with VaxEquity, with the goal of developing a next generation vaccines and therapeutics platform more potent than the Pfizer/BioNTech and Moderna pioneering messenger RNA (mRNA) vaccines.

The new partners have their sights set on a broad range of potential vaccine and therapeutic targets, with AstraZeneca seeing...

More from Business

More from Scrip

Second Quarter M&A Activity Looks Like More Of The Same, Mostly

 
• By 

The biopharma sector booked nearly the same number of acquisitions in each of the past two quarters, according to Evaluate data, but there are some encouraging signs in Q2.

How Teva Is Expanding Innovation To Fuel ‘Pivot To Growth’

 

Teva VP-global R&D and chief medical officer Eric Hughes talked to Scrip about building the company’s innovative pipeline in its growth-acceleration phase.

2025’s Biggest Launches – Half-Year Progress Report

 

Trial setbacks and extra regulatory scrutiny have hit the progress of some new drugs towards expected approvals this year, but early successes have boosted the commercial prospects of others. Fears of disruption from changes at the US FDA are so far unfounded.